They demonstrated that immunosuppressive M2 TAMs expressing FRβ promote tumor progression in a mouse model of ovarian cancer, pointing out FRβ as a potential therapeutic target in combination with chemo- or immunotherapy (200). This evidence concerns the gene FOLR2 and neoplasm.